Autologous Dendritic Cell Vaccine Optimization for Therapy of Patients with Disseminated Malignant Ne
Abstract
Immunobiological features of the dendritic cells (DC) were studied for the production of DC-vaccine (DCV) optimization. DC were differentiated in vitro in GM-CSF (previously studied concentration 72 ng/ml and IL-4 0–45 ng/ml containing medium. GM-CSF compounds by Pharmsynthez (Russia) and Cell Genix (Germany) and IL-4 by Cell Genix (Germany) were used. Comparative assays of mature and immature DC immunophenotype using different GM-CSF compounds was performed. CD1а, CD83, CD86, CD80, CCR7 и HLA DR are recommended optimal markers of DC for the standardization of technologic process. Flow cytometry and immunocytochemistry assays revealed no differences in mature DC markers expression (p>0,05). This indicates the expediency of Pharmsynthez (Russia) GM-CSF usage for DCV production. Optimal IL-4 concentrations (5–15 ng/ml) providing qualitative characteristics for DCV production were found using second level one-way polynomial model.
References
1. Балдуева И.А., Новик А.В., Моисеенко В.М., Нехаева Т.Л. Клиническое исследование (II фаза) вакцины на основе аутологичных дендритных клеток с иммунологическим адъювантом у больных с меланомой кожи // Вопросы онкологии. 2012. Т. 58, № 2. С. 212–221.
2. Леплина О.Ю., Насонова Г.В., Тихонова М.А. и др. IFNα-индуцированные дендритные клетки у больных множественной миеломой // Сибирский онкологический журнал. 2009. № 6 (36). С. 37–43.
3. Моисеенко В.М., Балдуева И.А. Принципы создания и использования лечебных вакцин в онкологии // Российский онкологический журнал. 2011. № 2. С. 49–53.
4. Медик В.А., Токмачев М.С., Фишман Б.Б. Статистика в медицине и биологии. М.: Медицина, 2000. Т. 1. 454 с.
5. Семилетова Ю.В., Анисимов В.В., Вагнер Р.И. Лечение больных первичной меланомой кожи. Современное состояние проблемы // Сибирский онкологический журнал. 2010. № 4 (40). С. 71–77.
6. Ahn J.S., Agrawal B. IL-4 is more effective than IL-13 for in vitro differentiation of dendritic cells from peripheral blood mononuclear cells // Int. Immunol. 2005. Vol. 17 (1). P. 1337–1346.
7. Bohnenkamp H.R., Ноll T. Development of a standardized protocol for reproducible generation of matured monocyte-derived dendritic cells suitable for clinical application // Cytotechnology. 2003. Vol. 42 (3). P. 121–131.
8. Chiang C.L., Maier D.A., Kandalaft L.E. et al. Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate // J. Transl. Med. 2011. Vol. 9. P. 198–230.
9. Draube A., Klein-Gonzalez N., Mattheus S. et al. Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-Analysis // PLoS One. 2011. Vol. 6 (4). E. 18801. doi: 10.1371/journal.pone.0018801.
10. Hettihewa L.M. Prolonged expression of MHC class I - peptide expression in bone marrow derived retrovirus transfected matured dendritic cells by continuous centrifugation in the presence of IL-4 // Ind. J. Med. Res. 2011. Vol. 134 (5). P. 672–678.
11. Ning J., Morgan D., Pamphilon D. A Rapid Culture Technique Produces Functional Dendritic-Like Cells from Human Acute Myeloid Leukemia Cell Lines // J. Biomed. Biotechnol. 2011. Vol. 2011. 172965. doi: 10.1155/2011/172965. Epub. 2011. Dec 5.
Review
For citations:
Nehaeva T.L. Autologous Dendritic Cell Vaccine Optimization for Therapy of Patients with Disseminated Malignant Ne. Siberian journal of oncology. 2013;(3):52-56. (In Russ.)
Views:
573
Email this article 
